TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 55 years~* HBsAg \> 1000 IU / ml~* HDAg+~* HDV RNA +~* No detectable antibodies to HIV, HCV or CMV.~* Non cirrhotic~* Willingness to utilize adequate contraception while being treated with REP 213-Ca and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~* Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 25 kg/m2~Exclusion Criteria:~* Evidence of cardiovascular disease~* Evidence of autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* ANA (anti-nuclear antibody) positive~* Fibroscan and Fibromax showing evidence of advanced cirrhosis.~* Any history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 90,000, PMN count \< 1,500 or HCT \< 33%~* Evidence of significant heavy metal load in whole blood.~* AFP \> 100 ng/ml or the presence of a hepatic mass suggestive of HCC~* Bilirubin above the normal range~* ALT \> 5x ULN~* Creatinine \> 1.5 mg/dl~* Serum albumin \< 35 mg/ml~* The presence of diabetes (whether controlled or uncontrolled)~* Another serious medical disorder~* A serious psychiatric disorder~* Evidence of hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making IV infusion too difficult~* Patient not willing to come every week to receive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2139-Ca + Pegasys (TM) (Type: EXPERIMENTAL): REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of ocular allergies within the past 24 months.~* Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.~Exclusion Criteria:~* Any presence of active ocular infection or history of an ocular herpetic infection.~* Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.~* Have any planned surgery during the study or 30 days after the study.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lastacaft® (Type: ACTIVE_COMPARATOR): One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
- Pataday™ (Type: ACTIVE_COMPARATOR): One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
- Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) (Type: PLACEBO_COMPARATOR): One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 70 years of age~* Females of reproductive potential must agree to take acceptable contraceptive precautions for the duration of the study~Exclusion Criteria:~* Patient has a history of hypersensitivity to niacin or niacin-containing products~* Patient is currently experiencing menopausal hot flashes~* Patient consumes more than 2 alcoholic beverages per day~* Patient has poorly controlled Type 1 or Type 2 diabetes mellitus~* Patient engages in vigorous exercise or an aggressive diet regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Male/Female with histologically confirmed GCT with review by the Department of Pathology at this center.~* Patients with advanced GCT, including patients with:~measurable or evaluable disease,~* patients with only elevated serum tumor markers (AFP and/or HCG), or~* patients with known residual disease after postchemotherapy surgery. Eligible patients must have established clinical resistance to cisplatin by their failure to achieve a durable CR to a cisplatin-based regimen.~* Prior treatment limited to ≤ 6 prior cycles (≤ four cycles preferred) of cisplatin. (GROUP A)~* Prior therapy \> 6 cycles of cisplatin. (GROUP B)~* Therapy must have been discontinued at least 3 weeks before entry onto protocol.~* Patients must have one or more unfavorable prognostic factors for achieving a CR to cisplatin-based salvage therapy. These are:~* Extragonadal primary site.~* Testis/ovarian primary site with the best response of an IR to first-line therapy, or a partial response with normal tumor markers of six months or less in duration.~* Prior treatment with ifosfamide-containing therapy~* General medical condition sufficient to allow for general anesthesia at the time of pheresis catheter placement.~* Patients must have negative serology for Human Immunodeficiency Virus.~* Laboratory criteria for protocol entry:~WBC ≥ 3000/ul Platelets 3 100,000/ul Cr Clearance \> 50 cc/min\*~\* (unless renal dysfunction is due to tumor obstructing the ureters in which case eligibility will be determined by the Principal Investigator).~* Age ≥ 15 years.~* Signed informed consent.~Exclusion Criteria:~* Presence of active infection~* Concurrent treatment with chemotherapy or~* Inability to comply with the treatment protocol or to undergo the specified follow-up tests for safety or effectiveness.~* Prior high-dose therapy with AuBMT.~* Patients must have recovered from recent surgery.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy administered with G-CSF and PBSC support (Type: EXPERIMENTAL): The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Continue RISS Block in Thoracotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age undergoing elective thoracic surgery~* American Society of Anesthesiologists (ASA) physical status I-III grade~Exclusion Criteria:~* Patient refusal~* History of psychiatric and cognitive disorders.~* Patients allergic to the drugs used in the study~* Emergent surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Rhomboid Intercostal and Subserratus Plane Block (Type: ACTIVE_COMPARATOR): Standart postoperative analgesia + Continue Rhomboid Intercostal and Subserratus Plane Block
- Control Group (Type: OTHER): Standart postoperative analgesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (equal or older than 18 years) of both sexes admitted in the Department of Clinical Hematology who develop a febrile neutropenia. Including fever with unknown source and fever secondary to infection focus of clinical diagnosis without laboratory confirmation.~* Informed consent signed.~Exclusion Criteria:~* Fever with etiologic diagnosis.~* Patients with epilepsy.~* Pregnant or lactating women.~* Patients with HIV infection.~* Patients with severe renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Empirical antimicrobial treatment discontinuation
- Control Arm (Type: ACTIVE_COMPARATOR): Standard empirical antimicrobial treatment discontinuation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus~* Patient is not pregnant or breastfeeding~* Male or female patient unlikely to conceive~* Patient not on an antihyperglycemic drug~Exclusion Criteria:~* Patient has history of type 1 diabetes mellitus~* Patient has history of ketoacidosis~* Patient requires insulin within 8 weeks prior to start of study~* Patient on weight loss program and is not in maintenance phase~* Patient taking weight loss medication within 8 weeks prior to start of study~* Patient on or likely to require = 14 days or repeated courses of corticosteroids~* Patient taking immunosuppressive/immunomodulating medication~* Patient taking digoxin or other cardiac medication~* Patient has undergone surgical general anesthesia within 30 days prior to start of study~* Patient taking investigational drug within 8 weeks prior to start of study~* Patient is diagnosed with liver disease~* Patient has chronic myopathy, progressive neurological/neuromuscular disorder~* Patient has with severe cardiac conditions within the last 6 months~* Patient is Human immunodeficiency virus (HIV) positive~* Patient has hematological disorder~* Patient has history of malignancy~* Patient has history of alcohol or drug abuse within the past 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg/100 mg (Type: ACTIVE_COMPARATOR): Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
- Sitagliptin 200 mg/200 mg (Type: ACTIVE_COMPARATOR): Phase A and B: Oral tablets of sitagliptin 200 mg q.d
- Placebo/Sitagliptin 100 mg (Type: PLACEBO_COMPARATOR): Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
- Placebo/Sitagliptin 200 mg (Type: PLACEBO_COMPARATOR): Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine in Coronary Artery Bypass Graft (CABG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.~Exclusion Criteria:~Excluded are patients:~* with age \> 80 years old~* scheduled for concomitant valve surgery~* scheduled for coronary surgery without cardiopulmonary bypass~* with peripheral vascular disease aﬀecting the upper limbs~* with acute coronary syndrome within the previous 4 weeks~* on inotropic or mechanical circulatory support before induction of anaesthesia~* with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)~* with active inflammatory diseases, infectious diseases or known malignancy~* under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents~* with known hypersensitivity-allergy to colchicine~* under chronic treatment with colchicine~* with severe renal failure (eGFR \< 35 ml/min/1.73 m2)~* with hepatic failure (Child - Pugh class B or C)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Patients taking placebo
- Colchicine (Type: EXPERIMENTAL): Active treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Milgamma® and Milgamma® Compositum Step-therapy in Patients With Acute Non-specific Low Back Pain Receiving Modern NSAID

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent including data protection declaration according to the local legislation.~* Acute non-specific low back pain less than 21 days (= 3 weeks).~* Low back pain treatment with (1) modern NSAIDs (preferential/selective COX-2 inhibitors) or (2) modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma®/ Milgamma® compositum prescribed (but not started yet) in frames of routine medical practice.~* Prescribed (but not started yet) step-therapy with Milgamma® to be followed by Milgamma® compositum in accordance with locally approved instruction for medical use (for the group planned to be treated with Milgamma®/ Milgamma® compositum step-therapy).~* Pain intensity according to Numerical Rating Scale (NRS) ≥4 points ≤9 at the time of enrollment.~* In case of presence of previous episodes of acute non-specific low back pain in medical history, the last one had resolved at least 30 days before the start of current episode.~Exclusion Criteria:~* History or presence of any disease that, in the opinion of the investigator, might confound the results of the study, poses an additional risk to the subject during participation in the study or can change pain perception (examples of such possible conditions: any malignancy, stomach ulcer, duodenal ulcer, chronic heart failure, bronchial asthma, psychiatry disorders, epilepsy, Parkinson Disease etc).~* Spinal surgery/rehabilitation in the last 12 months.~* Acute back pain that is attributable to any known or suspected specific identifiable cause (e.g. discogenic radiculopathy, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumor).~* Severe scoliosis.~* Use of NSAIDs or vitamins B within 2 months prior to enrollment into the study.~* Necessity to use myorelaxants or antidepressants for treatment of acute non-specific low back pain.~* Prior use of non-pharmacological treatment (physiotherapy, heat treatment (e.g. heat patch, hot water bottle) or topically applied medicinal products to the back area, procaine blocks) within the last 3 days before study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- NSAIDs group (Type: None): Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
- NSAIDs+Milgamma+Milgamma compositum group (Type: None): Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Negative Beta Glucan in ICU Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In the ICU for \>2 days AND~  * Systemic antibiotics on days 1-3 of ICU OR~ * Central venous catheter on days 1-3 of ICU~* AND at least 2 of:~  * Total parenteral nutrition on days 1-3 of ICU~ * Any dialysis on days 1-3 of ICU~ * Major surgery in the 7 days before admission in the ICU~ * Pancreatitis in the 7 days before admission in the ICU~ * Use of corticosteroids for at least 3 days in the 7 days before admission~ * Use of other immunosuppressive agents in the 7 days before admission in the ICU~* In addition, the patient must have at least one of the following:~  * Fever (axillary temperature \>37.5 oC)~ * Hypothermia (axillary temperature \<35 oC)~ * Hypotension~ * Unexplained acidosis~ * Unexplained elevation in C-reactive protein~Exclusion Criteria:~* Antifungal for \>3 days~* Allergy to an echinocandin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin (Type: EXPERIMENTAL): Patients at risk will receive therapy with anidulafungin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-infected~2. Age \>=18 years~3. Tuberculin skin test positive or negative~4. Laboratory:~   * Hemoglobin (Hgb) \>6.5 gm/dl;~  * Neutrophil count \>1,000 cells/mm3;~  * Platelets \>75,000/mm3;~  * AST (SGOT) \<122 U/L;~  * Creatinine \<1.5 mg/dl;~  * Beta HCG = negative~5. Karnofsky performance status \>=60~6. Signed informed consent~Exclusion Criteria:~1. History of TB in the last 3 years or current active TB~2. History of noncompliance to chronic therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous vs limited isoniazid (Type: EXPERIMENTAL): The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Anesthetics for Pain Reduction Prior to IV Line Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \> 18 y.o.~* Ability to speak, read, an/or understand English~* Ability to communicate a level of pain via the specified pain scale~* A written order exists for an intravenous peripheral catheter insertion for the patient~Exclusion Criteria:~* Lidocaine allergy~* Buffered lidocaine allergy~* Benzyl alcohol allergy~* Non-English speaking~* Non-responsive or unable to understand or report pain score (ex. intubated in the ICU)~* Inability to place catheter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): 1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
- Buffered Lidocaine (Type: EXPERIMENTAL): 1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine
- Bacteriostatic Normal Saline (Type: EXPERIMENTAL): Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete